Israeli imaging analysis software developer CathWorks has raised $30 million in a series C round of investment funding. CathWorks said the round was led by Deerfield Management.
CathWorks has developed the FFRangio fractional flow reserve (FFR) analysis software, which was cleared by the U.S. Food and Drug Administration in December 2018.
FFRangio is designed to deliver FFR guidance for optimizing percutaneous coronary intervention (PCI) procedures, without the invasiveness of a conventional FFR procedure. It uses data derived from images acquired during a coronary angiography exam, providing a 3D reconstruction of the entire coronary tree with FFR values along each vessel.
